Swedish Orphan Biovitrum Ab · OMXSTO:SOBI
Swedish Orphan Biovitrum Ab — Sobi — Investor Presentation (October 2024)
35 slides from Swedish Orphan Biovitrum Ab's investor presentation, October 2024
Slide 1: This is Sobi – Investor Presentation October 2024
This is Sobi D Investor Presentation October 2024
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains certain forward-looking statements with respect to certain of the Company’s current expectations and projections about future events. These statements, which sometimes use words such as “intend,” “proposed,” “plan,” “expect,” and words of similar
Slide 3: Table of contents
Table of contents Slide Sobi Key facts and business model 4 Latest results – Q3 and business area update 12 Sustainability at Sobi 27 Pipeline and upcoming news flow 31 IR contacts 35 Notes 36
Slide 4: Sobi's mission is to transform the lives of people with rare and debilitating diseases
Sobi’s mission is to transform the lives of people with rare and debilitating diseases Sobi Strategy Growing Portfolio Strategic Portfolio 1,800 employees focused on rare diseases Listed on Nasdaq Lead in Haematology Operating in 30 countries and serving ̴70 markets Stockholm: SOBI 5 medicines in la
Slide 5: Rare diseases are an attractive market and expected to grow faster than general pharma
Rare diseases are an attractive market and expected to grow faster than general pharma • ~7,000 rare disease have been identified with only an Sobi well positioned within rare diseases estimated 130 with marketed treatments Current Sobi areas • High medical unmet need and treatments offering signifi
Slide 6: Business model - source, develop and commercialise in the rare disease space
Business model - source, develop and commercialise in the rare disease space 2018 2019 2020 2022 2023 Acquisitions Source Licensing 7 medicines in 9 projects in development Develop (Phase 2 through registration) Europe +6% Commercialise 2023: Revenue: SEK 22,123 M North America + 6% (+12% at CER) In
Slide 7: Strong record of successful achievements in delivering medicines to rare disease patients
Strong record of successful achievements in delivering medicines to rare disease patients around the world Selected examples from the Sobi portfolio Source Novimmune Dova Apellis CTI Pharma ITP - FDA approval 2018 PNH - EU approval 2021 MF – FDA approval 2022 pHLH - FDA approval 2018 EU approval 202
Slide 8: Growth driven by core business area and all regions
Growth driven by core business area and all regions Sales (SEK B) Sales (SEK B) Specialty Care Immunology Haematology Europe North America Royalty Rest of World 22.1 22.1 18.8 18.8 15.3 15.5 15.3 15.5 14.2 14.2 9.1 9.1 6.5 6.5 2017 2018 2019 2020 2021 2022 2023 2017 2018 2019 2020 2021 2022 2023 8
Slide 9: Strategic portfolio set to be the main contributor to our revenue
Strategic portfolio set to be the main contributor to our revenue Strong fundamentals for future growth • Strategic Portfolio with ongoing launches and international diversification Strategic portfolio including Aspaveli/Empaveli, Doptelet, Gamifant, Vonjo, Zynlonta, Potential new medicines* Beyfort
Slide 10: Management Team
Management Team 10 sobi.com/executive committee
Slide 11: Latest results - Q3 2024 and business area update
Latest results - Q3 2024 and business area update
Slide 12: Demand growth in strategic portfolio in Q3 2024
Demand growth in strategic portfolio in Q3 2024 Positive progress in clinical development milestones High double-digit performance at CER Revenue Q3 - SEK 6,894 M, +39% (excluding RSV revenue grew 16%) Adjusted EBITA margin 43% Sobi Strategy Strategic portfolio1 grew 113% in Q3 • Beyfortus® royaltie
Slide 13: Robust growth across business areas and regions
Robust growth across business areas and regions YTD growth 24% driven by new approvals and momentum of launches Revenue by segment Revenue by region Q3 2024 change ratio Q3 2024 change ratio SEK M % % SEK M % % Haematology 4,000 +18 58 Europe 2,319 +14 33 North America 1,969 +15 29 – Haemophilia 2,2
Slide 14: Strategic portfolio – 56% of revenue in Q3
Strategic portfolio – 56% of revenue in Q3 Q3 Q3 Jan-Sep SEK M Change at CER 2024 2023 2024 Altuvoct 129 n/a n/a 134 Aspaveli/Empaveli 270 169 66% 760 Doptelet* 987 650 57% 2,671 Gamifant 405 438 -3% 1,365 Vonjo 379 347 13% 1,046 Zynlonta 29 15 96% 68 Altuviiio royalty 152 42 >200% 400 Beyfortus roy
Slide 15: Growth portfolio and pipeline progression
Growth portfolio and pipeline progression Pipeline* On market portfolio Altuviiio Beyfortus royalty royalty sHLH/MAS US FDA Fast Track 3 important products/indications short-term milestones achieved Designation SEL-212 100% YTD growth YTD Growth CRG Filed US FDA under Fast Track Designation C3G/IC-M
Slide 16: Altuvoct already showing rapid adoption in Germany
Altuvoct already showing rapid adoption in Germany Sobi Haemophilia A market share increasing by more than 6% Altuvoct Launch • Rapid patient adoption in Germany with sales of SEK 129 M • Patients coming from Elocta and competitive treatments (including non-factor products) • Sobi Market Share (Eloc
Slide 17: Aspaveli PNH & Nephrology - Positive Phase 3 results in rare kidney diseases
Aspaveli PNH & Nephrology - Positive Phase 3 results in rare kidney diseases Solid Aspaveli/Empaveli SEK 270 M PNH +66% Q3 • Continued strong growth momentum across EU, International and Canada as more patients switch to Aspaveli / Empaveli seeking improved control of their PNH • Q3 SEK 270 M (+66%
Slide 18: Sobi's view on pegcetacoplan in C3G – IC-MPGN
Sobi’s view on pegcetacoplan in C3G – IC-MPGN #1 We remain confident in a diagnosed patient population of at least 8k patients with C3G or IC-MPGN in Europe We are confident in pegcetacoplan’s blockbuster potential Additional potential opportunity in Japan and selected international markets #2 Incre
Slide 19: Doptelet continues to show strong momentum across all regions
Doptelet continues to show strong momentum across all regions Doptelet SEK 1,039 M +65% Q3 • Continued strong momentum in the business driven by increase market share gains in all regions • Doptelet delivers a favorable product profile with proven efficacy, convivence and favorable tolerability • Mi
Slide 20: Vonjo showing continued growth momentum
Vonjo showing continued growth momentum Vonjo SEK 379 M +13% Q3 • 12% quarter on quarter growth (13% YoY) • Field activity level significantly increased • Product awareness increased to >70%1 • Our long-term growth strategy is to tap into the potential related to: • New indications • International m
Slide 21: Elocta & Alprolix: Continued patient growth and geographical expansion
Elocta & Alprolix :Continued patient growth and geographical expansion Elocta Alprolix SEK 1,119 M Elocta SEK 575 M -9% Q3 • Sales impacted by order phasing in +8% Q3 International and Altuvoct launch in Germany Alprolix • Growth in number of patients, geographic expansion • Partly offset by continu
Slide 22: Gamifant set to complete filing in sHLH/MAS by year-end; Kineret growth
Gamifant set to complete filing in sHLH/MAS by year-end Kineret: Continued solid growth, + 21% in Q3 Gamifant Kineret SEK 405 M Gamifant SEK 699 M -3% Q3 • 1,000th patient treated +21% Q3 • Positive patient volumes • Q3 impacted by destocking / variation in patient treatment Kineret • Growth in all
Slide 23: Q3 2024 Revenue and profit & loss
Q3 2024 Revenue and profit & loss Q3 Q3 Full-year Total revenue (SEK M) Amounts in SEK M 2024 2023 Change 2023 Total revenue 6,894 5,168 33% 22,123 Haematology Immunology Specialty Care 1,2 Adjusted Gross profit 5,604 4,033 39% 17,162 6 844 6 894 1,2 298 311 Adjusted Gross margin 81% 78% 78% 6 256 1
Slide 24: Outlook 2024
Outlook 2024 Updated Revenue Anticipated to grow by a mid-teens percentage at CER1 Adjusted EBITA margin Anticipated to be in the mid-30s percentage of revenue 1. Constant exchange rates. 24
Slide 25: Sustainability at Sobi
O) @sobl Sustainability at Sobi
Slide 26: Sobi's sustainability strategy supports our strategic business priorities
Sobi’s sustainability strategy supports our strategic business priorities Maintain commitment Always act to patients responsibly Sustainability indices Index 2023 score • Access to treatment • An inclusive and diverse MSCI A (top 26%) • Patient centricity & workplace • Safe, healthy and fair Sustain
Slide 27: Maintain commitment to patients
Maintain commitment to patients For more details: Sustainability performance | Sobi Access to treatment Humanitarian aid Patient centricity • ~ 36,000 people treated* with • Four international patient councils to medicines from Sobi. advise on early clinical development. • Sobi’s main medicines acce
Slide 28: Always act responsibly
Always act responsibly For more details: Sustainability performance | Sobi Caring for employees Reduced footprint Responsible sourcing Compliance • Gender composition (%) • A 77% reduction in CO2- intensity between 2016 95% Mean score 64 95% and 2023 (from 0,3 to 0,07 between completed Code of of So
Slide 29: Pipeline and upcoming news flow
Pipeline and upcoming news flow
Slide 30: Significant events in 2024
Significant events in 2024 Anticipated major pipeline news flow SEL-212 Altuvoct Aspaveli Gamifant FDA filing EU approval VALIANT data FDA filing ongoing 2024 H1 2024 H2 Altuvoct– Haemophilia A: Doptelet – ITP: Regulatory approval in EU Regulatory submission in Japan Paediatric submission in US Paed
Slide 31: Continued R&D momentum in 2025
Continued R&D momentum in 2025 Anticipated major pipeline news flow 2025 Altuvoct – Haemophilia A • FREEDOM (Phase 3b) initial study data Aspaveli / Empaveli – Nephrology • EU submission • Japan submission Gamifant1 – sHLH / MAS • US decision • Japan submission SEL-212 – Chronic refractory gout • US
Slide 32: Current development pipeline
Current development pipeline Major ongoing clinical studies and medicines in registration in a major region or country Pipeline news flow 2024 Q4 Gamifant – sHLH / MAS in rheumatological diseases • Regulatory submission in the US (Still’s disease cohort) Doptelet – ITP • Paediatric submission in the
Slide 33: Sobi IR contacts
Sobi IR contacts Investors page on sobi.com Gerard Tobin Jen Kretzmann Jörgen Winroth Head of Investor Relations Manager of Stakeholder Senior advisor Investor gerard.tobin@sobi.com Communication and Corporate Relations, North America +41 79 286 28 83 Access Jorgen.Winroth@sobi.com jennifer.kretzman
Slide 34: Notes on Haemophilia and RSV business
Notes on Haemophilia and RSV business Haemophilia • Sobi and Sanofi collaborate on the development and commercialisation of Alprolix and Elocta/Eloctate. The companies also collaborate on the development and commercialisation of efanesoctocog alfa, or Altuviiio in the US. • Sobi has final developmen
Slide 35: Thank you
Thank you Sobi is a trademark of Swedish Orphan Biovitrum AB (publ). © 2023 Swedish Orphan Biovitrum AB (publ) – All rights reserved Swedish Orphan Biovitrum AB (publ) SE-112 76 Stockholm • Sweden www.sobi.com